Stocks
enVVeno Medical CorporationNVNO
NASDAQHealthcareMedical Devices$6.65
Price as of · delayed, not real-time
A clinical-stage medical device company developing a tissue-based venous valve replacement for chronic venous insufficiency. Its lead product, the VenoValve, is in U.S. pivotal trials, with an FDA premarket approval submission expected in 2026. Investors track the stock for its potential to address an unmet need in a large patient population, though it carries high clinical and regulatory risk.
52W Range: $6.55-$26.70
Congressional Interest in enVVeno Medical Corporation (NVNO)
No congressional trades have been disclosed for enVVeno Medical Corporation (NVNO) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading NVNO?
No congressional trades found for this stock.